Literature DB >> 1637678

Reversal of multidrug resistance by surfactants.

D M Woodcock1, M E Linsenmeyer, G Chojnowski, A B Kriegler, V Nink, L K Webster, W H Sawyer.   

Abstract

Cremophor EL, a pharmacologically inactive solubilising agent, has been shown to reverse multidrug resistance (MDR). Using flow cytometric evaluation of equilibrium intracellular levels of daunorubicin (DNR), we found that eight other surface active agents will also reverse MDR. All the active detergents contain polyethoxylated moieties but have no similarities in their hydrophobic components. The properties of three polyethoxylated surfactants that showed the lowest toxicities, Cremophor, Tween 80 and Solutol HS15, were examined in more detail. The concentrations of Tween 80 and Solutol required to reverse DNR exclusion were 10-fold lower than for Cremophor. However while concentrations greater than or equal to 1:10(2) of the former two surfactants resulted in breakdown of cells, even 1:10 of Cremophor did not lyse cells. Studies of the effects of Cremophor on the uptake and efflux of DNR in normal and MDR cell types showed that Cremophor increases intracellular DNR primarily by locking the rapid efflux from the cells. This blockage of drug efflux may be mediated by a substantial alteration in the fluidity of cell membranes induced by Cremophor, as shown by decreased fluorescence anisotropy of a membrane probe. Consistent with these data, coinjection of adriamycin plus Cremophor into mice carrying a multidrug resistant P388 transplantable tumour significantly increased the survival time of the mice compared with adriamycin treatment alone.

Entities:  

Mesh:

Substances:

Year:  1992        PMID: 1637678      PMCID: PMC1977900          DOI: 10.1038/bjc.1992.217

Source DB:  PubMed          Journal:  Br J Cancer        ISSN: 0007-0920            Impact factor:   7.640


  16 in total

1.  Measurement of multidrug-resistance messenger RNA in urogenital cancers; elevated expression in renal cell carcinoma is associated with intrinsic drug resistance.

Authors:  Y Kakehi; H Kanamaru; O Yoshida; H Ohkubo; S Nakanishi; M M Gottesman; I Pastan
Journal:  J Urol       Date:  1988-04       Impact factor: 7.450

Review 2.  Multidrug resistance.

Authors:  J A Moscow; K H Cowan
Journal:  J Natl Cancer Inst       Date:  1988-03-02       Impact factor: 13.506

3.  Circumvention of vincristine and Adriamycin resistance in vitro and in vivo by calcium influx blockers.

Authors:  T Tsuruo; H Iida; M Nojiri; S Tsukagoshi; Y Sakurai
Journal:  Cancer Res       Date:  1983-06       Impact factor: 12.701

4.  Reversal of the multidrug resistance phenotype with cremophor EL, a common vehicle for water-insoluble vitamins and drugs.

Authors:  D M Woodcock; S Jefferson; M E Linsenmeyer; P J Crowther; G M Chojnowski; B Williams; I Bertoncello
Journal:  Cancer Res       Date:  1990-07-15       Impact factor: 12.701

5.  Intrinsic drug resistance in human kidney cancer is associated with expression of a human multidrug-resistance gene.

Authors:  A T Fojo; D W Shen; L A Mickley; I Pastan; M M Gottesman
Journal:  J Clin Oncol       Date:  1987-12       Impact factor: 44.544

6.  Flow cytometric screening for selective toxicity to multidrug-resistant cells.

Authors:  O S Frankfurt
Journal:  J Natl Cancer Inst       Date:  1987-10       Impact factor: 13.506

7.  Properties and the locations of a set of fluorescent probes sensitive to the fluidity gradient of the lipid bilayer.

Authors:  K R Thulborn; W H Sawyer
Journal:  Biochim Biophys Acta       Date:  1978-08-04

8.  Solutol HS 15, nontoxic polyoxyethylene esters of 12-hydroxystearic acid, reverses multidrug resistance.

Authors:  J S Coon; W Knudson; K Clodfelter; B Lu; R S Weinstein
Journal:  Cancer Res       Date:  1991-02-01       Impact factor: 12.701

9.  The solvents cremophor EL and Tween 80 modulate daunorubicin resistance in the multidrug resistant Ehrlich ascites tumor.

Authors:  E Friche; P B Jensen; M Sehested; E J Demant; N N Nissen
Journal:  Cancer Commun       Date:  1990

10.  Levels of expression of the mdr1 gene and glutathione S-transferase genes 2 and 3 and response to chemotherapy in multiple myeloma.

Authors:  M E Linsenmeyer; S Jefferson; M Wolf; J P Matthews; P G Board; D M Woodcock
Journal:  Br J Cancer       Date:  1992-03       Impact factor: 7.640

View more
  32 in total

1.  Cationic lipid-mediated transfection of differentiated Caco-2 cells: a filter culture model of gene delivery to a polarized epithelium.

Authors:  A N Uduehi; S H Moss; J Nuttall; C W Pouton
Journal:  Pharm Res       Date:  1999-12       Impact factor: 4.200

Review 2.  Molecular properties of bacterial multidrug transporters.

Authors:  M Putman; H W van Veen; W N Konings
Journal:  Microbiol Mol Biol Rev       Date:  2000-12       Impact factor: 11.056

Review 3.  Role of formulation vehicles in taxane pharmacology.

Authors:  L van Zuylen; J Verweij; A Sparreboom
Journal:  Invest New Drugs       Date:  2001-05       Impact factor: 3.850

4.  The effects of pluronics block copolymers and Cremophor EL on intestinal lipoprotein processing and the potential link with P-glycoprotein in Caco-2 cells.

Authors:  Fergal Seeballuck; Marianne B Ashford; Caitriona M O'Driscoll
Journal:  Pharm Res       Date:  2003-07       Impact factor: 4.200

5.  Paclitaxel nanocrystals for overcoming multidrug resistance in cancer.

Authors:  Yang Liu; Leaf Huang; Feng Liu
Journal:  Mol Pharm       Date:  2010-06-07       Impact factor: 4.939

6.  Nanomedicine in the diagnosis and therapy of neurodegenerative disorders.

Authors:  A V Kabanov; H E Gendelman
Journal:  Prog Polym Sci       Date:  2007       Impact factor: 29.190

Review 7.  CNS drug delivery: opioid peptides and the blood-brain barrier.

Authors:  Ken A Witt; Thomas P Davis
Journal:  AAPS J       Date:  2006-02-24       Impact factor: 4.009

8.  Loss of orally administered drugs in GI tract.

Authors:  Yogeshkumar Nanasaheb Gavhane; Adhikrao Vyankatrao Yadav
Journal:  Saudi Pharm J       Date:  2012-04-20       Impact factor: 4.330

Review 9.  Multidrug resistance in cancer chemotherapy.

Authors:  N H Patel; M L Rothenberg
Journal:  Invest New Drugs       Date:  1994       Impact factor: 3.850

Review 10.  Pharmacological effects of formulation vehicles : implications for cancer chemotherapy.

Authors:  Albert J ten Tije; Jaap Verweij; Walter J Loos; Alex Sparreboom
Journal:  Clin Pharmacokinet       Date:  2003       Impact factor: 6.447

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.